CA2808061A1 - Hepatitis c virus inhibitors - Google Patents

Hepatitis c virus inhibitors Download PDF

Info

Publication number
CA2808061A1
CA2808061A1 CA2808061A CA2808061A CA2808061A1 CA 2808061 A1 CA2808061 A1 CA 2808061A1 CA 2808061 A CA2808061 A CA 2808061A CA 2808061 A CA2808061 A CA 2808061A CA 2808061 A1 CA2808061 A1 CA 2808061A1
Authority
CA
Canada
Prior art keywords
alkyl
mmol
cap
independently selected
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2808061A
Other languages
English (en)
French (fr)
Inventor
Pothukanuri Srinivasu
Samayamunthula Venkata Satya Arun Kumar Gupta
Makonen Belema
John A. Bender
Omar D. Lopez
Qi Chen
Richard A. Rampulla
Nicholas A. Meanwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2808061A1 publication Critical patent/CA2808061A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2808061A 2010-08-12 2011-08-10 Hepatitis c virus inhibitors Abandoned CA2808061A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37307010P 2010-08-12 2010-08-12
US61/373,070 2010-08-12
US13/198,529 2011-08-04
US13/198,529 US20120195857A1 (en) 2010-08-12 2011-08-04 Hepatitis C Virus Inhibitors
PCT/US2011/047211 WO2012021591A1 (en) 2010-08-12 2011-08-10 Hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
CA2808061A1 true CA2808061A1 (en) 2012-02-16

Family

ID=44534668

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2808061A Abandoned CA2808061A1 (en) 2010-08-12 2011-08-10 Hepatitis c virus inhibitors

Country Status (11)

Country Link
US (1) US20120195857A1 (enExample)
EP (1) EP2603504A1 (enExample)
JP (1) JP5805763B2 (enExample)
CN (1) CN103249731A (enExample)
AR (1) AR082681A1 (enExample)
BR (1) BR112013003101A2 (enExample)
CA (1) CA2808061A1 (enExample)
EA (1) EA024171B1 (enExample)
MX (1) MX2013001579A (enExample)
TW (1) TW201211032A (enExample)
WO (1) WO2012021591A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2012533569A (ja) 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
CA2809261A1 (en) 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
EP2651928A4 (en) * 2010-12-15 2014-06-18 Abbvie Inc ANTI-VIRAL COMPOUNDS
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG193291A1 (en) 2011-03-04 2013-10-30 Newgen Therapeutics Inc Alkyne substituted quinazoline compound and methods of use
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
EP2730572B1 (en) 2011-07-09 2015-09-16 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis c virus inhibitors
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
BR112014010401A8 (pt) 2011-11-03 2017-12-19 Theravance Inc Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2862755A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
WO2013163262A1 (en) 2012-04-25 2013-10-31 Theravance, Inc. Piperazine-piperidine compounds as hepatitis c virus inhibitors
CN104364236B (zh) * 2012-05-09 2018-01-16 拜尔农作物科学股份公司 5‑卤代吡唑二氢茚基甲酰胺
CN103420991B (zh) * 2012-05-17 2017-07-07 乳源东阳光药业有限公司 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
TW201412709A (zh) * 2012-09-28 2014-04-01 Sunshine Lake Pharma Co Ltd 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
WO2014082379A1 (en) * 2012-11-29 2014-06-05 Sunshine Lake Pharma Co.,Ltd. Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention
TW201439084A (zh) * 2012-11-29 2014-10-16 Sunshine Lake Pharma Co Ltd 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們在藥物中的應用
CN103848818B (zh) * 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
JP6306874B2 (ja) * 2013-12-20 2018-04-04 住友化学株式会社 臭素化合物の製造方法
WO2015110048A1 (en) * 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
CN105085493A (zh) * 2014-04-15 2015-11-25 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
CN105272972B (zh) * 2014-05-30 2018-12-11 上海唐润医药科技有限公司 具有抗病毒活性的苯并杂环己二烯衍生物
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
ES2686352T3 (es) * 2014-06-12 2018-10-17 Gilead Sciences, Inc. Compuestos antivíricos
TWI675029B (zh) * 2014-12-16 2019-10-21 大陸商廣東東陽光藥業有限公司 作為丙型肝炎抑制劑的橋環化合物及其製備方法
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN108349945B (zh) * 2015-11-06 2021-10-29 江苏豪森药业集团有限公司 Hcv抑制剂、其制备方法与应用
WO2017153919A1 (en) 2016-03-08 2017-09-14 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
MY203207A (en) 2018-02-28 2024-06-14 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
US11634389B2 (en) 2018-11-28 2023-04-25 The Regents Of The University Of Michigan Succinate dehydrogenase inhibitors and methods of making and using the same
EP4543878A1 (en) 2022-06-21 2025-04-30 Astrazeneca AB N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
DE102004036971B4 (de) 2004-07-30 2009-07-30 Advanced Micro Devices, Inc., Sunnyvale Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
AU2008350327B2 (en) * 2008-02-12 2013-09-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20120124A1 (es) * 2008-12-03 2012-03-17 Presidio Pharmaceuticals Inc Derivados 2-pirrolidin-3-il-1h-imidazol, como inhibidores de la proteina no estructural 5a del virus de la heptitis c
NZ619205A (en) * 2009-05-13 2015-04-24 Gilead Pharmasset Llc Antiviral compounds
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN102791687B (zh) * 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂

Also Published As

Publication number Publication date
EP2603504A1 (en) 2013-06-19
BR112013003101A2 (pt) 2016-06-28
WO2012021591A1 (en) 2012-02-16
EA201390190A1 (ru) 2013-06-28
EA024171B1 (ru) 2016-08-31
MX2013001579A (es) 2013-05-22
CN103249731A (zh) 2013-08-14
US20120195857A1 (en) 2012-08-02
AR082681A1 (es) 2012-12-26
JP5805763B2 (ja) 2015-11-04
JP2013533317A (ja) 2013-08-22
TW201211032A (en) 2012-03-16

Similar Documents

Publication Publication Date Title
CA2808061A1 (en) Hepatitis c virus inhibitors
US9776981B2 (en) Hepatitis C virus inhibitors
EP2146984B1 (en) Hepatitis c virus inhibitors
US9006455B2 (en) Hepatitis C virus inhibitors
US8377980B2 (en) Hepatitis C virus inhibitors
EP2414352B1 (en) Hepatitis c virus inhibitors
EP2673271B1 (en) Hepatitis c virus inhibitors
EP2707365B1 (en) Hepatitis c virus inhibitors
CA2812699A1 (en) Hepatitis c virus inhibitors
US9561212B2 (en) Hepatitis C virus inhibitors
HK1144194B (en) Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
HK1144194A1 (en) Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170810